ArticleOphthalmology science2026
Structure-Function Correlations Using Artificial Intelligence-Extracted Retinal Layer Attenuation Measurements in OCT in Eyes with Geographic Atrophy.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the structure-function relationships between retinal layer attenuation on OCT and a range of functional assessments in patients with geographic atrophy (GA). Design: Retrospective analysis of 2 phase III clinical trials. Subjects: One thousand five hundred and nineteen subjects with GA who were enrolled in phase III studies investigating Lampalizumab: Chroma (NCT02247479) and Spectri (NCT02247531). Methods: Structural retinal features were assessed by artificial intelligence (AI)-based automated segmentation algorithms on OCT images to calculate metrics for outer retinal layer attenuations: loss for external limiting membrane (ELM), ellipsoid zone (EZ), and retinal pigment epithelium (RPE). Functional measures included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and reading speed collected in all patients. Microperimetry was collected in a subset of patients. Main Outcome Measures: Correlations (Pearson r) between the OCT layer loss metrics with visual function measures. Results: Cross-sectional analysis did not show any notable correlations between loss areas of each layer for the full OCT scan range and BCVA but did show correlations with LLVA (EZ loss area r = -0.39). After spatially defining regions using the ETDRS circles, notable correlations were observed between BCVA and ELM loss area within the central 1 mm diameter circle area (r = -0.46) and for LLVA with the central 3 mm diameter circle even after exclusion of the central 1 mm diameter region. Microperimetry outcomes correlated with OCT layer losses; the number of scotomatous points correlated equally well with total macular ELM and EZ losses (r = 0.67), mean macular sensitivity had the highest correlations with EZ loss areas, and perilesional sensitivity or responding sensitivity showed the highest correlation with the difference in EZ and RPE loss area (r = -0.50, r = -0.48). Conclusions: The current analyses using AI-based OCT layer losses provide new insights into the spatial dependency of the relationship between anatomical and functional changes in GA. The differential associations noted between BCVA and LLVA with central and paracentral macular pathology, respectively, suggest alternative pathways for diverse aspects of visual function and help inform the design of anatomical and functional assessments for clinical trials in GA. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.